Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

2016995 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 17, Issue 9, pp. 1248-1260

Field-Weighted Citation Impact: 58.14